National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Salivary Gland Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 07/11/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Stage I Major Salivary Gland Cancer






Stage II Major Salivary Gland Cancer






Stage III Major Salivary Gland Cancer






Stage IV Major Salivary Gland Cancer






Recurrent Major Salivary Gland Cancer






Get More Information From NCI






Changes to This Summary (07/11/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
The Nation's Investment in Cancer Research FY 2010

Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Stage Information

TNM Definitions
AJCC Stage Groupings

In general, tumors of the major salivary glands are staged according to size, extraparenchymal extension, lymph node involvement (in parotid tumors, whether or not the facial nerve is involved), and presence of metastases.[1-4] Tumors arising in the minor salivary glands are staged according to the anatomic site of origin (e.g., oral cavity and sinuses). (Refer to the PDQ summaries on Laryngeal Cancer Treatment, Lip and Oral Cavity Cancer Treatment, Nasopharyngeal Cancer Treatment, Hypopharyngeal Cancer Treatment, and Paranasal Sinus and Nasal Cavity Cancer Treatment for more information.)

Clinical stage, particularly tumor size, may be the critical factor to determine the outcome of salivary gland cancer and may be more important than histologic grade.[5,6] Diagnostic imaging studies may be used in staging. With excellent spatial resolution and superior soft tissue contrast, magnetic resonance imaging (MRI) offers advantages over computed tomographic scanning in the detection and localization of head and neck tumors. Overall, MRI is the preferred modality for evaluation of suspected neoplasms of the salivary glands.[7]

The American Joint Committee on Cancer (AJCC) has designated staging by TNM classification.[5]

TNM Definitions

Primary tumor (T)

  • TX: Primary tumor cannot be assessed
  • T0: No evidence of primary tumor
  • T1: Tumor 2 cm or less in greatest dimension without extraparenchymal extension*
  • T2: Tumor more than 2 cm but 4 cm or less in greatest dimension without extraparenchymal extension*
  • T3: Tumor more than 4 cm and/or tumor having extraparenchymal extension*
  • T4a: Tumor invades skin, mandible, ear canal, and/or facial nerve
  • T4b: Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

* [Note: Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.]

Regional lymph nodes (N)

  • NX: Regional lymph nodes cannot be assessed
  • N0: No regional lymph node metastasis
  • N1: Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
  • N2: Metastasis in a single ipsilateral lymph node, more than 3 cm but 6 cm or less in greatest dimension; or in multiple ipsilateral lymph nodes, 6 cm or less in greatest dimension; or in bilateral or contralateral lymph nodes, 6 cm or less in greatest dimension
    • N2a: Metastasis in a single ipsilateral lymph node, more than 3 cm but 6 cm or less in greatest dimension
    • N2b: Metastasis in multiple ipsilateral lymph nodes, 6 cm or less in greatest dimension
    • N2c: Metastasis in bilateral or contralateral lymph nodes, 6 cm or less in greatest dimension
  • N3: Metastasis in a lymph node more than 6 cm in greatest dimension

Distant metastasis (M)

  • MX: Distant metastasis cannot be assessed
  • M0: No distant metastasis
  • M1: Distant metastasis
AJCC Stage Groupings

Stage I

  • T1, N0, M0

Stage II

  • T2, N0, M0

Stage III

  • T3, N0, M0
  • T1, N1, M0
  • T2, N1, M0
  • T3, N1, M0

Stage IVA

  • T4a, N0, M0
  • T4a, N1, M0
  • T1, N2, M0
  • T2, N2, M0
  • T3, N2, M0
  • T4a, N2, M0

Stage IVB

  • T4b, any N, M0
  • Any T, N3, M0

Stage IVC

  • Any T, any N, M1

References

  1. Spiro RH, Huvos AG, Strong EW: Cancer of the parotid gland. A clinicopathologic study of 288 primary cases. Am J Surg 130 (4): 452-9, 1975.  [PUBMED Abstract]

  2. Fu KK, Leibel SA, Levine ML, et al.: Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer 40 (6): 2882-90, 1977.  [PUBMED Abstract]

  3. Levitt SH, McHugh RB, Gómez-Marin O, et al.: Clinical staging system for cancer of the salivary gland: a retrospective study. Cancer 47 (11): 2712-24, 1981.  [PUBMED Abstract]

  4. Kuhel W, Goepfert H, Luna M, et al.: Adenoid cystic carcinoma of the palate. Arch Otolaryngol Head Neck Surg 118 (3): 243-7, 1992.  [PUBMED Abstract]

  5. Major salivary glands (parotid, submandibular, and sublingual). In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer, 2002, pp 53-8. 

  6. Spiro RH: Factors affecting survival in salivary gland cancers. In: McGurk M, Renehan AG, eds.: Controversies in the Management of Salivary Gland Disease. Oxford, UK: Oxford University Press, 2001, pp 143-50. 

  7. Shah GV: MR imaging of salivary glands. Magn Reson Imaging Clin N Am 10 (4): 631-62, 2002.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov